European Union Approval for Taxotere® (docetaxel) in Prostate Cancer
European Union Approval for Taxotere® (docetaxel) in Prostate Cancer Strasbourg, France - November 4, 2004 - Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere® (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone-refractory) metastatic prostate cancer. The Commission approval is based on the results of a large landmark phase III clinical trial, TAX 327, which demonstrated that a Taxotere-based regimen significantly reduced the risk of death by 24 percent